- Home
- EDU vs LEGN Comparison
EDU vs LEGN Comparison
Compare EDU & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDU
- LEGN
- Stock Information
- Founded
- EDU 1993
- LEGN 2014
- Country
- EDU China
- LEGN United States
- Employees
- EDU N/A
- LEGN N/A
- Industry
- EDU Other Consumer Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- EDU Real Estate
- LEGN Health Care
- Exchange
- EDU Nasdaq
- LEGN Nasdaq
- Market Cap
- EDU 8.5B
- LEGN 6.3B
- IPO Year
- EDU 2006
- LEGN 2020
- Fundamental
- Price
- EDU $54.25
- LEGN $31.58
- Analyst Decision
- EDU Buy
- LEGN Strong Buy
- Analyst Count
- EDU 6
- LEGN 12
- Target Price
- EDU $57.87
- LEGN $70.82
- AVG Volume (30 Days)
- EDU 1.3M
- LEGN 1.3M
- Earning Date
- EDU 10-28-2025
- LEGN 11-12-2025
- Dividend Yield
- EDU 2.17%
- LEGN N/A
- EPS Growth
- EDU N/A
- LEGN N/A
- EPS
- EDU 2.27
- LEGN N/A
- Revenue
- EDU $4,987,826,000.00
- LEGN $796,838,000.00
- Revenue This Year
- EDU $10.42
- LEGN $68.68
- Revenue Next Year
- EDU $10.31
- LEGN $48.49
- P/E Ratio
- EDU $24.39
- LEGN N/A
- Revenue Growth
- EDU 7.29
- LEGN 74.75
- 52 Week Low
- EDU $40.66
- LEGN $27.34
- 52 Week High
- EDU $68.53
- LEGN $45.30
- Technical
- Relative Strength Index (RSI)
- EDU 43.20
- LEGN 40.56
- Support Level
- EDU $55.00
- LEGN $31.31
- Resistance Level
- EDU $60.33
- LEGN $32.50
- Average True Range (ATR)
- EDU 1.81
- LEGN 1.00
- MACD
- EDU -0.79
- LEGN 0.04
- Stochastic Oscillator
- EDU 16.62
- LEGN 6.49
About EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.